Study to Evaluate Impact SANKOM Patent Socks in Patients With CVI

NCT ID: NCT03445091

Last Updated: 2018-03-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-05
• Study Completion Date: 2018-04-01

Brief Summary

Clinical study to evaluate impact on quality of life in patients with Chronic Venous Insufficiency during 4 weeks period of using SANKOM® Patent Socks

Detailed Description

Despite the application of compression stockings looks simple, it must be remembered that inappropriately worn stockings have the potential to cause certain problems. Unevenly distributed and excess pressure may break the skin, especially in older, malnourished patients and those with thin, brittle skin.

Although an extreme case, it highlights the importance of careful assessment, application, and monitoring of compression stockings.

Typically, the stockings are safe and wearing them results in few or no complications, provided they're worn smoothly against the leg, without any folds. But some groups of people should avoid them, including those with peripheral neuropathy or any other condition that impacts skin sensation; a history of a peripheral arterial bypass grafting; peripheral artery disease; skin infection; dermatitis with oozing or fragile skin; massive leg swelling; or pulmonary edema from congestive heart failure. Each of these conditions presents a different series of risks. For example, for people with peripheral artery disease, stockings can worsen oxygen delivery in arteries with impaired blood flow. People who have sensory problems, such as those with peripheral neuropathy, may not feel when a compression stocking is too tight, which could impede circulation. And certain skin conditions or infections may worsen with a compression stocking covering and pressing on the area.

In general, if subject has any medical condition, he/she should talk with health care professional before using compression stockings to see if they are good candidate for them.

Since probability of side/adverse effects from IP use is considered as very low vs of high probability of expected positive effects.

Study Purpose and Design Multi-center, observational open label study aimed to evaluate an impact on quality of life in Chronic Venous Insufficiency patients using SANKOM® Patent Socks during 4 weeks

This study will involve a maximum of 30 subjects. Subjects will be followed through outpatient's observation.

Primary Objective

Improvement of QoL by scores of:

• Aberdeen Varicose Veins Questionnaire (AVVQ)
• CIVIQ-2 Venous Quality of Life Questionnaire

Secondary Objectives

Secondary Endpoints are:

• Improvement of US-examination picture
• Improvement of QoL by Subject's questionnaire

Conditions

Chronic Venous Insufficiency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Patients using investigational product

Open-label use of SANKOM Patent Socks

Group Type: EXPERIMENTAL

SANKOM Patent Socks

Intervention Type: DEVICE

Using compression socks to ease symptoms of patients with chronic venous insufficiency

Interventions

SANKOM Patent Socks

Using compression socks to ease symptoms of patients with chronic venous insufficiency

Intervention Type: DEVICE

Other Intervention Names

gradient compression socks

Eligibility Criteria

Inclusion Criteria

1. Subject is informed and given ample time and opportunity to think about his/her participation and has given his/her written informed consent before any procedure;

2. Subject is male or female, 35-65 years of age;

3. Subject with chronic venous insufficiency CEAP (C1, C2);

4. Subject can speak and understand Ukrainian or Russian language.

Exclusion Criteria

1. Subject participated in any clinical study (drug or device) within 6 months prior to the screening;

2. Subject unable to wear compression stockings;

3. Subject using other compression therapy.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InterMedService SA

OTHER

Sponsor Role: collaborator

Pharmaxi LLC

INDUSTRY

Sponsor Role: collaborator

Sankom SA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Serge M Mazourik, MD

Role: STUDY_CHAIR

Intermedservice

Locations

Kyiv City Clinical Hospital No 6

Kyiv, , Ukraine

Medical Consulting Center of Pechersk District

Kyiv, , Ukraine

Countries

Ukraine

Other Identifiers

Sankom-001

Identifier Type: -

Identifier Source: org_study_id